Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

11/30/2021 | 02:01am EST

Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 5 May 2022 has been appointed

In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the Nomination Committee shall consist of four members representing the three largest shareholders together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known shareholders as per the end of September.

Based on the above, the Nomination Committee in respect of the AGM that will be held in Malmö on 5 May 2022 has been established to consist of the following persons together representing approximately 25% of votes in the company:

  • Jørgen Thorball, chairman of the Nomination Committee, appointed by Sunstone Life Science Ventures II K/S;
  • Håkan Nelson, appointed by Øresund Healthcare Capital;
  • Marianne Flink, appointed by The Fourth Swedish National Pension Fund (AP4); and
  • Peter Benson, chairman of the board of directors.


The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2022 and on the company’s website, www.ascelia.com.

The duties of the Nomination Committee is to prepare and propose the following to the coming annual shareholders’ meeting: election of chairman at the shareholders’ meeting; election of chairman of the board of directors and other members of the board of directors; fees to the board of directors, divided between the chairman and other members, and any fees for committee work; election of auditor and fees to the auditor; and principles for appointment of the Nomination Committee.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address or alternatively via e-mail kb@ascelia.com. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 4 February 2022, to ensure that the proposals can be considered by the Nomination Committee.

© Modular Finance, source Nordic Press Releases

All news about ASCELIA PHARMA AB (PUBL)
2021Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
AQ
2021Ascelia Pharma AB Receives FDA Acceptance of IND Application for Oncoral Clinical Trial
CI
2021Results from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
2021Ascelia Pharma AB Announces Results from Orviglance comparison study to gadolinium pres..
CI
2021Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
2021QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
2021Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully
CI
2021ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -126 M -13,5 M -13,5 M
Net cash 2021 252 M 27,0 M 27,0 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 838 M 90,5 M 89,8 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float -
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 24,90 SEK
Average target price 58,00 SEK
Spread / Average Target 133%
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-16.58%90
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601